Zantac / Ranitidine Litigation (NDMA Contamination)

Zantac (ranitidine) was one of the most commercially successful pharmaceutical products in history. First approved by the FDA in 1983, it became the first drug to exceed $1 billion in annual sales and was eventually available over the counter in most countries. At its peak, an estimated 15 million Americans used ranitidine products annually for heartburn and acid reflux.

In September 2019, the online pharmacy Valisure submitted a citizen petition to the FDA reporting that ranitidine molecules are inherently unstable and can produce N-Nitrosodimethylamine (NDMA) — a potent probable human carcinogen — particularly when exposed to heat. Valisure's testing found NDMA levels exceeding 3,000,000 nanograms per tablet — more than 31,000 times the FDA's acceptable daily intake limit of 96 nanograms.

The discovery triggered a cascade of regulatory actions. The FDA initially requested voluntary recalls from manufacturers, then in April 2020 demanded the withdrawal of all ranitidine products from the U.S. market after its own testing confirmed that NDMA levels in ranitidine increase over time and with higher storage temperatures — conditions routinely encountered during shipping, warehousing, and home storage.

The litigation alleges that manufacturers knew or should have known about ranitidine's instability and NDMA-forming potential for decades. Scientific literature as early as the 1980s described the chemical susceptibility of the ranitidine molecule to nitrosamine formation.

NDMA (N-Nitrosodimethylamine) is classified by IARC as 'probably carcinogenic to humans' (Group 2A) and by the EPA as a 'probable human carcinogen.' It is a potent mutagen and carcinogen that primarily targets the liver but has been associated with multiple cancer types in animal studies.

The core scientific question in the Zantac litigation is whether the ranitidine molecule itself is unstable and generates NDMA — within the pill during storage or within the human body after ingestion. Valisure's testing and independent academic research suggest that ranitidine can degrade into NDMA through multiple pathways, including thermal decomposition and reaction with nitrites present in the stomach.

The federal MDL judge (Judge Rosenberg) concluded in December 2022 that plaintiffs' experts had not sufficiently established general causation linking Zantac-specific NDMA exposure to cancer using reliable methodologies. This Daubert ruling excluded plaintiffs' experts and led to dismissal of the federal MDL cases.

However, state court judges in Delaware and other jurisdictions have reached different conclusions regarding the admissibility of similar or identical expert testimony. Delaware courts have found the expert evidence sufficiently reliable to proceed to trial, highlighting the inherently subjective nature of Daubert gatekeeping decisions.

The scientific debate remains genuine. The NDMA contamination in ranitidine is established fact (the FDA withdrew the product). The disputed question is whether the specific levels and duration of NDMA exposure from Zantac use are sufficient to cause cancer in individual users.

Eligible individuals may include those who regularly used Zantac (brand name) or generic ranitidine products — whether prescription or over-the-counter — and were subsequently diagnosed with cancer, particularly bladder, stomach, liver, esophageal, pancreatic, or colorectal cancer. Given the drug's widespread availability and decades of use, the potentially affected population numbers in the millions.

IMPORTANT CAVEAT: The federal MDL was dismissed on causation grounds. State court litigation continues in some jurisdictions but not all. The viability of individual claims depends heavily on jurisdiction and the evolving state of the scientific evidence. This case requires careful attorney evaluation.

This eligibility information is general and informational only. Consult a licensed attorney.

Federal MDL: In December 2022, Judge Robin L. Rosenberg (S.D. Florida) excluded plaintiffs' general causation experts under the Daubert standard, leading to dismissal of about 14,000 federal cases. Plaintiffs have appealed to the U.S. Court of Appeals for the Eleventh Circuit. As of September 1, 2026, 847 cases were still pending on the MDL docket.

Delaware: A Delaware Superior Court judge initially allowed plaintiffs' experts to testify, but the Delaware Supreme Court reversed that ruling. On April 13, 2026, the Superior Court granted summary judgment to the defendants in all cases filed on or before December 1, 2025, finding that plaintiffs had not shown general causation. Plaintiffs filed a notice of appeal in May 2026.

Settlements: In 2024, GSK paid more than $2 billion to resolve what it said was more than 90% of its pending state court cases, and other manufacturers also settled many cases. Remaining claims depend largely on the outcome of the federal and Delaware appeals.

Sanofi, GSK, and other defendants have vigorously defended the Zantac litigation. They cite the federal MDL Daubert ruling as validation of their position that the scientific evidence is insufficient to establish causation. Defendants argue that:

• The levels of NDMA generated by ranitidine in real-world conditions are far lower than those used in animal carcinogenicity studies • Millions of people used ranitidine for decades without developing cancer • The FDA's decision to withdraw ranitidine was based on quality control concerns (unpredictable NDMA levels) rather than a determination that the product caused cancer • Plaintiffs' experts employed unreliable methodologies and extrapolations

Defendants have pointed to the federal Daubert ruling as a comprehensive judicial assessment of the scientific evidence. However, they face the challenge that state courts in multiple jurisdictions have reached opposite conclusions about the same or similar evidence.

In 2024, GSK paid more than $2 billion to resolve more than 90% of its pending Zantac cases, according to its SEC filings. Other former Zantac manufacturers also settled substantial numbers of state court cases.

There is no global settlement for the remaining claims. The dismissal of the federal MDL claims (2022) and the Delaware summary judgment ruling (April 2026) are both on appeal.

Past settlement amounts are not a guarantee of future results.